Emory Alzheimer's Disease Research Center

埃默里阿尔茨海默病研究中心

• 批准号: 10673939
• 负责人: JAMES J LAH
• 金额: $ 46.88万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10673939
• 关键词: Acceleration; African American; Alzheimer' s Disease; Area; Automobile Driving; Biological Markers; Biology; Blood Vessels; Cardiovascular Physiology; Cardiovascular system; Caucasians; Clinical; Clinical Research; Clinical Trials Unit; Collection; Data Analyses; Dementia; Dementia with Lewy Bodies; Development; Disease; Enrollment; Etiology; Funding; Goals; Individual; Institution; International; Lead; Lewy Body Disease; Lewy body pathology; Link; Longitudinal cohort; Measures; Medicine; Molecular; Movement Disorders; Parkinson Disease; Parkinson' s Dementia; Participant; Phenotype; Play; Positioning Attribute; Procedures; Process; Recommendation; Research; Research Activity; Research Project Grants; Role; System; Training Activity; United States National Institutes of Health; Validation; Vascular Cognitive Impairment; Work; biomarker discovery; clinical center; clinical phenotype; cohort; data management; data sharing; diagnostic tool; follow-up; improved; minority engagement; neuropathology; new therapeutic target; novel marker; operation; outreach; participant enrollment; racial disparity; recruit; research and development; research study; sample collection; success; symposium; vascular factor

SUMMARY/ABSTRACT: CLINICAL CORE The primary goals of the Clinical Core are to support and enhance research efforts of the Goizueta Alzheimer’s Disease Research Center (ADRC) at Emory to advance cutting-edge research to identify novel biomarkers and therapeutic targets while reducing racial disparities in AD research. The Clinical Core plays a central role in the Goizueta ADRC by engaging diverse research participants and driving activities that reflect the Center’s overall themes. To accomplish these goals, the Clinical Core has well-established processes to recruit, track, characterize, and retain a cohort of longitudinal research participants and to effectively coordinate activities and share data with other components of the ADRC and external partners. In the current funding period, the Clinical Core established a Longitudinal Biomarker Collection to support high-priority multicenter research projects, including the Accelerating Medicine Partnership for AD (AMP-AD) and Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD). Successful development of the LBC led to a competitive supplement to establish a Biomarker Core which will continue as a Core component in the ADRC renewal. Also, during the current cycle, we succeeded in our ambitious goal for increasing the diversity of our UDS cohort by enrolling an equal number of new African-American and Caucasian participants. This success supported the establishment of a Minority Engagement Core (MEC). Specific Aims for this renewal are to 1) Establish and maintain a diverse cohort of well-characterized research participants to support priorities in current ADRD research; 2) Advance biomarker discovery efforts by harmonizing procedures for sample collection and clinical phenotyping across multiple related projects and cohorts; and 3) Expand and integrate activities in ADRD, including vascular cognitive impairment and Lewy body diseases. Achieving these Specific Aims will advance the priorities identified in the National Alzheimer’s Project Act (NAPA) and recommendations from the NIH ADRD Research Summits, and will ultimately lead to effective diagnostic tools and treatments for individuals suffering from AD and related disorders.

摘要/摘要：临床核心 临床核心的主要目标是支持和加强阿尔茨海默氏症的研究工作 埃默里（Emory）的疾病研究中心（ADRC）促进尖端研究以识别新型生物标志物和 治疗靶标，同时减少AD研究中的种族分布。临床核心在 Goizueta ADRC通过参与潜水员的研究参与者和驾驶活动，以反映该中心的整体 主题。为了实现这些目标，临床核心具有良好的招募，跟踪， 表征并保留一系列纵向研究参与者并有效地协调活动 并与ADRC和外部合作伙伴的其他组件共享数据。在当前的资金期间， 临床核心建立了一个纵向生物标志物收集，以支持高优先级多中心研究 项目，包括AD的加速医学伙伴关系（AMP-AD）和分子机制 AD的血管病因（M2OVE-AD）。 LBC的成功开发导致了竞争性补充 建立生物标志物核心，该核心将继续作为ADRC续订的核心组成部分。另外，在 当前周期，我们成功地实现了通过注册来增加UDS队列多样性的雄心勃勃的目标 相等数量的新非裔美国人和高加索参与者。这一成功支持了机构 少数派参与核心（MEC）。续约的具体目标是1）建立和维护 各种各样的特征熟练的研究参与者，以支持当前ADRD研究的优先事项； 2） 通过协调样品收集和临床表型的程序来提高生物标志物发现工作 跨多个相关的项目和人群； 3）在ADRD中扩展和集成活动，包括 血管认知障碍和刘易身体疾病。实现这些具体目标将促进 在《国家阿尔茨海默氏症》（NAPA）中确定的优先事项和NIH ADRD的建议 研究峰会，并最终为苦难的个体提供有效的诊断工具和治疗 来自广告和相关疾病。